Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates (Q47265537)

12 January 2018

title

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates (English)

1 reference

12 January 2018

relapsing-remitting multiple sclerosis

main subject

multiple sclerosis

0 references

0 references

author

Jonathan Bartlett

2

1 reference

12 January 2018

Nick C. Fox

3

1 reference

12 January 2018

Valerie M Anderson

object named as

Valerie M Anderson

1

0 references

David H. Miller

5

object named as

David H Miller

1 reference

12 January 2018

author name string

Leonora Fisniku

4

1 reference

12 January 2018

publication date

25 October 2007

1 reference

12 January 2018

published in

Journal of Neurology

1 reference

12 January 2018

volume

254

1 reference

12 January 2018

issue

11

1 reference

12 January 2018

page(s)

1588-1594

1 reference

12 January 2018

Eight-year follow-up study of brain atrophy in patients with MS.

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-007-0599-3

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-007-0599-3

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-007-0599-3

Advances in functional and structural MR image analysis and implementation as FSL

21 January 2018

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans.

1 reference

12 December 2020

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center

1 reference

12 December 2020

The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI.

1 reference

12 December 2020

Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study

1 reference

12 December 2020

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta

1 reference

12 December 2020

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

1 reference

12 December 2020

Ventricular enlargement in MS: one-year change at various stages of disease

1 reference

12 December 2020

The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement.

1 reference

12 December 2020

The analysis of repeated 'direct' measures of change illustrated with an application in longitudinal imaging

1 reference

12 December 2020

Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI

1 reference

12 December 2020

Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets

1 reference

12 December 2020

Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups

1 reference

12 December 2020

Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype

1 reference

12 December 2020

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a

1 reference

12 December 2020

Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease

1 reference

12 December 2020

Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods

1 reference

12 December 2020

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

10.1007/S00415-007-0599-3

Identifiers

DOI

1 reference

12 January 2018

1 reference

12 January 2018